Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases
The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.
The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.
What's Your Reaction?
